Ally Bridge Group NY LLC boosted its position in Merus (NASDAQ:MRUS - Free Report) by 19.1% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 208,244 shares of the biotechnology company's stock after purchasing an additional 33,400 shares during the period. Merus makes up approximately 5.6% of Ally Bridge Group NY LLC's investment portfolio, making the stock its 3rd biggest holding. Ally Bridge Group NY LLC owned approximately 0.30% of Merus worth $10,404,000 at the end of the most recent quarter.
Several other large investors have also modified their holdings of MRUS. nVerses Capital LLC lifted its stake in shares of Merus by 750.0% during the 3rd quarter. nVerses Capital LLC now owns 1,700 shares of the biotechnology company's stock worth $85,000 after acquiring an additional 1,500 shares during the last quarter. US Bancorp DE bought a new stake in shares of Merus during the third quarter worth $103,000. Mirae Asset Global Investments Co. Ltd. lifted its position in shares of Merus by 24.7% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,467 shares of the biotechnology company's stock worth $118,000 after purchasing an additional 489 shares during the last quarter. Farallon Capital Management LLC purchased a new stake in shares of Merus during the second quarter valued at $237,000. Finally, ProShare Advisors LLC purchased a new position in Merus in the 2nd quarter worth about $242,000. Hedge funds and other institutional investors own 96.14% of the company's stock.
Merus Trading Down 2.0 %
Shares of NASDAQ:MRUS traded down $0.90 during trading on Thursday, reaching $44.97. The stock had a trading volume of 643,989 shares, compared to its average volume of 683,940. The firm's 50-day simple moving average is $50.12 and its 200 day simple moving average is $51.81. Merus has a one year low of $22.27 and a one year high of $61.61. The company has a market capitalization of $3.08 billion, a P/E ratio of -11.38 and a beta of 1.12.
Merus (NASDAQ:MRUS - Get Free Report) last announced its earnings results on Thursday, October 31st. The biotechnology company reported ($0.95) earnings per share for the quarter, missing the consensus estimate of ($0.90) by ($0.05). The firm had revenue of $11.77 million during the quarter, compared to analyst estimates of $9.11 million. Merus had a negative net margin of 680.61% and a negative return on equity of 38.89%. Equities research analysts forecast that Merus will post -3.89 earnings per share for the current fiscal year.
Analyst Ratings Changes
MRUS has been the subject of several research reports. UBS Group started coverage on shares of Merus in a research report on Thursday, October 24th. They issued a "buy" rating and a $72.00 price objective for the company. Needham & Company LLC reissued a "buy" rating and issued a $85.00 price objective on shares of Merus in a research note on Wednesday, November 20th. HC Wainwright reaffirmed a "buy" rating and set a $85.00 target price on shares of Merus in a research report on Friday, November 1st. Guggenheim upped their target price on Merus from $93.00 to $111.00 and gave the stock a "buy" rating in a report on Tuesday, October 1st. Finally, The Goldman Sachs Group assumed coverage on Merus in a research note on Thursday, November 21st. They set a "buy" rating and a $73.00 price target on the stock. One research analyst has rated the stock with a sell rating, twelve have given a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat.com, Merus has a consensus rating of "Buy" and an average target price of $85.45.
Read Our Latest Stock Report on MRUS
About Merus
(
Free Report)
Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1.
Read More
Before you consider Merus, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Merus wasn't on the list.
While Merus currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
